Drug
Naperiglipron clinical trials
Also written LY3549492.
- studies test it
- 10
- open now
- 1
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the naperiglipron studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Atorvastatin (1) · Midazolam (1) · Mazdutide (1) · Eloralintide (1) · Tirzepatide (1) · Macupatide (1)
Studies
Open first, then newest update. How each study uses naperiglipron is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Written as LY3549492
- A Study of LY3549492 in Healthy Weight Adult ParticipantsTerminatedPhase 2Eli Lilly and CompanyNCT07085468Written as LY3549492
- A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesTerminatedPhase 2Eli Lilly and CompanyNCT07030868Written as LY3549492
- A Study of LY3549492 in Healthy Participants and Participants With Overweight or ObesityCompletedPhase 1Eli Lilly and CompanyNCT07232732Written as LY3549492
- A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedPhase 2Eli Lilly and CompanyNCT06683508Written as LY3549492
- A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06869018Written as LY3549492
- A Study of LY3549492 in Chinese Participants With Type 2 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT07073170Written as LY3549492
- A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1Eli Lilly and CompanyNCT05327595Written as LY3549492
- A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06194500Written as [14C]-LY3549492
- A Study of LY3549492 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04758234Written as LY3549492
Codes
What other systems call naperiglipron · ClinicalTrials.gg INT016111
- UNII (FDA) BJN78TT46SNAPERIGLIPRONOne source FDA
- NCI Thesaurus C223294NaperiglipronOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BJN78TT46S | NAPERIGLIPRON | One source FDA |
| NCI Thesaurus | C223294 | Naperiglipron | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.